Oppenheimer lowered the firm’s price target on PMV Pharmaceuticals to $15 from $28 driven by removal of pipeline programs, extension of timelines for PC14586 and R282W programs, and additional adjustments for increased operating expenses and a dilutive financing. The firm keeps an Outperform rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PMVP: